Roche Could Increase Supply Of Tamiflu To U.S. Market
This article was originally published in The Pink Sheet Daily
The company says existing inventory of the flu therapy could be used this winter season. Roche is expecting double-digit sales growth for the year, but says investors should not expect a significant upswing in fourth quarter performance.
You may also be interested in...
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
Roche announced simultaneous U.S. and European submissions July 21; six-month review would set user fee date at mid-January. Roche is likely to highlight superiority to GlaxoSmithKline’s Epivir-HBV and efficacy in HBeAg-negative patients in promotions.
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.